Veludacigib

BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer[1].

Product Specifications

CAS Number

[2732902-08-6]

Product Name Alternative

BAY 2965501

UNSPSC

12352005

Target

DGK

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bay-2965501.html

Concentration

10mM

Purity

99.92

Solubility

DMSO : ≥ 100 mg/mL

Smiles

NC([C@@H](C)N(C1=CC=C(C=C1)F)C2=NC(N)=C(C(C3=CC=C(C=C3)OC)=O)S2)=O

Molecular Formula

C20H19FN4O3S

Molecular Weight

414.45

References & Citations

[1]Schubert N, et al. Phosphorylated extracellular signal-regulated kinase (pERK) activation in T effector cells as a target engagement biomarker for the DGKζ inhibitor BAY2965501 in clinical trials. Cancer Research, 2023, 83 (7_Supplement) : 2116-2116.|[2]Rienk Offringa, et al. 926 BAY 2965501: a highly selective DGK zeta inhibitor for cancer immunotherapy. Regular and Young Investigator Award Abstracts. Immune Cell Types and Biology.|[3]Schlicher L, et al. Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status. Front Immunol. 2023 Oct 31;14:1297175.